TANNQUILYNNE Trademark

Trademark Overview


On Wednesday, October 24, 2018, a trademark application was filed for TANNQUILYNNE with the United States Patent and Trademark Office. The USPTO has given the TANNQUILYNNE trademark a serial number of 88167507. The federal status of this trademark filing is REGISTERED as of Tuesday, May 18, 2021. This trademark is owned by SyneuRx International (Taiwan) Corp.. The TANNQUILYNNE trademark is filed in the Pharmaceutical Products category with the following description:

Syrups for pharmaceutical purposes for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, met...
tannquilynne

General Information


Serial Number88167507
Word MarkTANNQUILYNNE
Filing DateWednesday, October 24, 2018
Status700 - REGISTERED
Status DateTuesday, May 18, 2021
Registration Number6351061
Registration DateTuesday, May 18, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 2, 2021

Trademark Statements


Goods and ServicesSyrups for pharmaceutical purposes for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment and prevention of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Transdermal patches for use in the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Natural dietary supplements for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 6, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSyneuRx International (Taiwan) Corp.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Party NameSyneuRx International (Taiwan) Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Party NameSyneuRx International (Taiwan) Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Trademark Events


Event DateEvent Description
Saturday, October 27, 2018NEW APPLICATION ENTERED
Tuesday, November 6, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 7, 2018ASSIGNED TO EXAMINER
Friday, December 7, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 26, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 15, 2019PUBLISHED FOR OPPOSITION
Tuesday, January 15, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 12, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 13, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, August 13, 2019SOU EXTENSION 1 FILED
Tuesday, August 13, 2019SOU EXTENSION 1 GRANTED
Thursday, August 15, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 27, 2020SOU TEAS EXTENSION RECEIVED
Thursday, February 27, 2020SOU EXTENSION 2 FILED
Thursday, February 27, 2020SOU EXTENSION 2 GRANTED
Saturday, February 29, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 24, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, July 24, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, July 24, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, July 24, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, July 24, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 24, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, September 10, 2020TEAS PETITION TO AMEND BASIS RECEIVED
Thursday, September 10, 2020SOU TEAS EXTENSION RECEIVED
Friday, September 18, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sunday, October 18, 2020ASSIGNED TO PETITION STAFF
Thursday, September 10, 2020SOU EXTENSION 3 FILED
Wednesday, October 28, 2020SOU EXTENSION 3 GRANTED
Wednesday, October 28, 2020PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Wednesday, October 28, 2020ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
Thursday, October 29, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 31, 2020NOTICE OF ALLOWANCE CANCELLED
Thursday, December 31, 2020CASE RETURNED TO EXAMINATION
Wednesday, February 10, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 2, 2021PUBLISHED FOR OPPOSITION
Tuesday, March 2, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 18, 2021REGISTERED-PRINCIPAL REGISTER
Monday, May 18, 2026COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED